Last reviewed · How we verify
ASP0819
ASP0819 is a small molecule inhibitor of the PI3K delta subunit.
ASP0819 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of relapsing forms of multiple sclerosis.
At a glance
| Generic name | ASP0819 |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, ASP0819 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Treatment of relapsing forms of multiple sclerosis
Common side effects
- Upper respiratory tract infection
- Nausea
- Diarrhea
- Headache
- Muscle spasms
Key clinical trials
- A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP0819 CI brief — competitive landscape report
- ASP0819 updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI